Application of Lifileucel in Advanced Non-Small Cell Lung Cancer Patients Resistant to Immune Checkpoint Inhibitors This article, authored by Adam J. Schoenfeld and numerous other top scholars, was published in the 2024 edition of Cancer Discovery. The study is based on a multi-center phase II clinical trial aiming to evaluate the efficacy and safe...

St. Jude Survivorship Portal: Analysis and Sharing of Large-Scale Clinical and Genomic Data of Pediatric Cancer Survivors Research Background In the United States, the five-year survival rate for childhood cancer has increased from about 60% in the 1970s to over 85% today. Despite the significant improvement in survival rates, these childhood cance...

Introduction In the process of healthy hematopoiesis, a group of hematopoietic stem cells (HSC) contribute to all blood-related lineages. However, as we age, this process often leads to clonal hematopoiesis (CH), meaning the expansion of clones originating from a particular HSC, which then occupies a significant portion of blood cells and platelets...

In the current field of tumor treatment, precision medicine continues to be a research hotspot and development trend. With the advancement of science and technology, we have begun to more accurately understand the characteristics of tumor cells and their dependencies for survival, in hopes of finding new therapeutic targets. Particularly, strategie...

Research Report: The Regulatory Role of ROR2 in Pancreatic Cancer Cell Plasticity Background Introduction Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with most patients lacking the possibility of a cure. This is partly due to the difficulty in early detection. One of the characteristics of PDAC is its extensive tumor cell heterogene...

The Role of IL-33 in Promoting Tumor Growth in Pancreatic Cancer Tissue and its Potential as a Therapeutic Target Background Introduction Pancreatic Cancer (PDA) is one of the most lethal malignancies worldwide, characterized by rapid clinical progression and poor treatment responses, with a five-year survival rate of only 13%. In the United States...

ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer Academic Background and Research Motivation Existing research evidence suggests that cancer cell lineage plasticity and epigenetic reprogramming enable them to evade lineage-dependent targeted therapy by adopting lineage plasticity. Howev...

The Costimulatory Role of CD28 Enhances the Function of CAR-NK Cells through the LCK/CD3ζ/ZAP70 Signaling Axis Research Background and Objective Chimeric Antigen Receptor (CAR) T-cell therapy has shown significant effects in treating certain advanced cancer patients. However, CAR-T cell therapy has many limitations, such as high cost, complex prepa...

CRISPR-Dependent Screening in Primary Hematopoietic Stem Cells Identifies KDM3B as Specific Susceptibility for IDH2 and TET2 Mutant Genotypes Background and Significance Clonal Hematopoiesis (CH) refers to the abnormal growth of genetically distinct subclones of cells initiated by specific mutations in Hematopoietic Stem Cells (HSCs). This phenomen...

Mechanisms of Resistance to Carcinogenic KRAS Inhibition in Pancreatic Cancer Background Pancreatic Ductal Adenocarcinoma (PDAC) is a highly lethal disease. Most patients are diagnosed at an advanced stage and typically die within 12 months, primarily due to limited treatment options and poor response to standard chemotherapy. KRAS is the most crit...